Response within 8 days and durable response
In the pivotal, Phase 3, randomised study:
- 65.6% of patients on Doptelet achieved the ≥50 x 109/L platelet target by day 8*1
- Doptelet patients achieved a median of 12.4 weeks at or above target without rescue therapy*1
Effect and durable response regardless of prior treatment experience
- After switching to Doptelet, 93% of patients reached the ≥50 x 109/L platelet target†2
Doptelet is well tolerated and the most frequently reported adverse reactions (≥1/10) were headache and fatigue4
- Exposure-adjusted TEAEs 4.3% per patient week vs 6.6% with placebo*1
No food-type restrictions and no liver function monitoring4
- Doptelet should be taken with food – without any restrictions on meal composition, helping your patients stay compliant with therapy1,4–6
- Doptelet is the only oral TPO-RA that has not been associated with significant hepatotoxicity in clinical trials; no liver function monitoring is required1,4
*Vs 0.0% with placebo (P<0.0001), Phase 3 study. †Retrospective, observational TPO-RA switch study.
Doptelet is indicated for the treatment of severe thrombocytopenia in adult patients with chronic liver disease who are scheduled to undergo aninvasive procedure. 4 Doptelet is indicated for the treatment of primary chronic immune thrombocytopenia (ITP) in adult patients who are refractory to other treatments (e.g. corticosteroids, immunoglobulins). 4
ITP, immune thrombocytopenia; TEAE, treatment-emergent adverse event; TPO-RA, thrombopoietin receptor agonist.
References
1. Jurczak W, Chojnowski K, Mayer J, et al. Phase 3 randomised study of avatrombopag, a novel thrombopoietin receptor agonist for the treatment of chronic immune thrombocytopenia. Br J Haematol. 2018;183(3):479-490 2. Al-Samkari H, Jiang D, Gernsheimer T, et al. Adults with immune thrombocytopenia who switched to avatrombopag following prior treatment with eltrombopag or romiplostim: A multicentre US study. Br J Haematol. 2022;197(3):359-366. 3. Al-Samkari H, Jiang D, Gernsheimer T, et al. Durability of Platelet Response When Switching from Eltrombopag or Romiplostim to Avatrombopag in Immune Thrombocytopenia (ITP): A Multicenter Study.Blood. 2021;138(1):1015-1016. 4. Doptelet Summary of Product Characteristics. 22/05/2025. 5. Cheloff AZ, Al-Samkari H. Avatrombopag for the treatment of immune thrombocytopenia and thrombocytopenia of chronic liver disease. J Blood Med. 2019;10:313-321. Published 2019 Sep 5. 6. Tsykunova G, Ghanima W. Avatrombopag for the Treatment of Adult Patients with Chronic Immune Thrombocytopenia (cITP): Focus on Patient Selection and Perspectives. Ther Clin Risk Manag. 2022;18:273-286. Published 2022 Mar 24.